Company Description
TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally.
The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and treg function to identify and characterize therapeutic targets, using computational mapping, which uses in silico tools and a human tissue bank and atlas of human treg gene expression to identify pathways in tissue immune regulation; the Treg Atlas, which recreates tissue states in tregs and reprograms blood-derived Tregs to recreate human tissue-specific pathways in vitro for target validation; and the Phenotypic Assay Cascade, a suite of high-throughput functional fingerprinting assays that test targets across donors and inflammatory contexts.
The company develops TRB-061 an investigational tumor necrosis factor receptor 2 (TNFR2) agonist and fragment crystallizable-fusion (Fc-fusion) protein designed to selectively agonize TNFR2 to activate and expand Tregs in inflamed tissues.
The company also develops TRB-071, an agonist designed to augment tissue Tregs and block an inflammatory signaling pathway, for inflammatory bowel disease.
Additionally, it advances TRB-051, a partnered modulator of immune effector cells, for autoimmune and inflammatory diseases including lupus with cutaneous involvement.
The company also advances preclinical-stage programs addressing tissue Treg biology informed by the Deep Biology Platform.
TRex Bio, Inc. was incorporated in 2018 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 9, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Marion Erwin |
Contact Details
Address: 269 East Grand Avenue, Suite 300 South San Francisco, California 94080 United States | |
| Phone | (650) 567-5582 |
| Website | trex.bio |
Stock Details
| Ticker Symbol | TRXB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 2139097 |
| CUSIP Number | 89531N100 |
| ISIN Number | US89531N1000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| M. Johnston Erwin, Jr. | Chief Executive Officer and Chair |
| Laura Berner | Chief Operating Officer |
| Brandon Hants | Chief Financial Officer |
| Ariella Kelman | Chief Medical Officer |
| Ali Zarrin | Chief Scientific Officer |
| Carol G. Gallagher | Director and Lead Independent Director |
| Alexandra Cantley | Director |
| Travis Coy | Director |
| Julie Gilmore | Director |
| Peter Hirth | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | SCHEDULE 13G | Filing |
| Oct 16, 2026 | SCHEDULE 13D | Filing |
| Oct 16, 2026 | SCHEDULE 13D | Filing |
| Oct 15, 2026 | SCHEDULE 13G | Filing |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 9, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 9, 2026 | 424B4 | Prospectus |
| Oct 8, 2026 | EFFECT | Notice of Effectiveness |
| Oct 8, 2026 | CERT | Certification by an exchange approving securities for listing |
| Oct 6, 2026 | 8-A12B | Registration of securities |